文献速递妇科生殖医学

复方口服避孕药和/或抗雄激素与胰岛素增敏剂治疗多囊卵巢综合征的比较:系统综述与荟萃分析

Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2018-01-01

该系统综述与荟萃分析纳入33项随机对照试验、共1521名不寻求生育的成年多囊卵巢综合征女性,比较复方口服避孕药和/或抗雄激素与胰岛素增敏剂的疗效与安全性,结果显示抗雄激素治疗对多毛症状和子宫内膜保护优于二甲双胍,联合二甲双胍对BMI和糖耐量有额外获益。

要点

  • 复方口服避孕药和/或抗雄激素对多毛症状和子宫内膜保护优于二甲双胍。
  • 二甲双胍对BMI和HOMA-IR的改善优于复方口服避孕药和/或抗雄激素。
  • 复方口服避孕药和/或抗雄激素联合二甲双胍可减弱前者对BMI的负面影响并改善空腹血糖。

核心结论

  • 复方口服避孕药和抗雄激素对多毛症状和子宫内膜保护比二甲双胍更有效,联合二甲双胍对BMI和糖耐量有正面影响。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和EMBASE截至2017年9月16日,最终纳入33项随机对照试验、共1521名不寻求生育的成年多囊卵巢综合征女性。

主要发现

  • 复方口服避孕药和/或抗雄激素与二甲双胍之间的多毛评分平均差异不显著;排除一项纳入多数严重多毛女性的研究后,效果显著有利于复方口服避孕药和/或抗雄激素。
  • 仅纳入含抗雄激素的研究与二甲双胍比较时,差异显著有利于抗雄激素治疗。
  • 复方口服避孕药和/或抗雄激素联合二甲双胍与单用复方口服避孕药和/或抗雄激素在全部患者中相似。
  • 干预后规律月经存在的比值比有利于复方口服避孕药治疗。
  • BMI的平均差异有利于二甲双胍;复方口服避孕药对BMI的负面影响在与二甲双胍联合时被减弱。

关键数值与推荐

  • 高血压患病率和血脂谱影响的总体证据质量非常低,多毛、BMI和血压值的证据质量低,子宫内膜保护和糖耐量的证据质量高。

临床怎么用

  • 复方口服避孕药和抗雄激素对多毛症状和子宫内膜保护比二甲双胍更有效,与二甲双胍联合对BMI和糖耐量有正面影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen excess is a key pathogenetic mechanism in polycystic ovary syndrome (PCOS), although hyperinsulinism also contributes to androgen secretion. Therapeutic approaches for adult patients not seeking fertility include combined oral contraceptives (COC), antiandrogens (AA) and/or insulin sensitizers, although these practices are supported by limited high-quality evidence. OBJECTIVE AND RATIONALE: We aimed to assess the efficacy and safety of these common treatments for PCOS by conducting a meta-analysis of RCTs with the following review questions: Which is the more appropriate therapeutic approach for hyperandrogenic symptoms, hyperandrogenemia, and ovulatory dysfunction in adult women with PCOS not seeking fertility; What is the impact on classic cardiometabolic risk factors of the more common treatments used in those women; Does the combination of the antiandrogenic therapy plus metformin have any impact on efficacy or cardiometabolic profile? SEARCH METHODS: We searched PubMed and EMBASE for articles published up to 16 September 2017. After deleting duplicates, the abstracts of 1522 articles were analysed. We subsequently excluded 1446 articles leaving 76 studies for full-text assessment of eligibility. Of them, 43 articles were excluded. Hence, 33 studies and 1521 women were included in the quantitative synthesis and in the meta-analyses. Meta-analyses calculated mean differences (MD), standardized mean differences (SMD), odds ratio (OR) and 95% CIs. Heterogeneity and inconsistency across studies was assessed by χ2 test and Higgins's I2 statistics. Quality and risk of bias of individual studies were assessed according to the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. We then used the approach recommended by the Grading of Recommendations, Assessments, Development, and Evaluation (GRADE) group to indicate the global quality of evidence for a selection of primary outcomes. OUTCOMES: Regarding efficacy, the MD in hirsutism score between COC and/or AA and metformin were not significant. The exclusion of one single study including most women with severe hirsutism yielded a significant effect in favour of COC and/or AA. When only those studies including an AA were compared with metformin, there were significant differences favouring antiandrogenic therapy. The combination of COC and/or AA with metformin was similar to COC and/or AA therapy alone in the whole group of patients. Post-intervention OR for the presence of regular menses favoured COC therapy. In terms of cardiometabolic impact, the MD in BMI were in favour of metformin. The negative effect of COC therapy on BMI was blunted by its combination with metformin. The MD in homoeostasis model assessment of insulin resistance (HOMA-IR) were also in favour of metformin therapy compared to COC and/or AA. The combination of COC and/or AA and metformin decreased MD in HOMA with respect to antiandrogenic therapy alone. There were no significant post-intervention SMD in circulating glucose levels between COC and/or AA and metformin. However, adding metformin to COC and/or AA yielded a beneficial effect on fasting glucose levels. Post-intervention OR for abnormal glucose tolerance showed no significant differences between COC and/or AA and metformin, although after excluding studies including an AA as a comparator (without COC) a significant effect in favour of metformin therapy was observed. There were no significant differences among therapies in lipid profile, blood pressure or prevalence of hypertension. The global quality of evidence was very low when addressing the impact of the treatments explored on prevalence of hypertension and lipid profiles, low in the case of hirsutism, BMI and blood pressure values, and high for endometrial protection and glucose tolerance. WIDER IMPLICATIONS: These data provide further scientific evidence for the choice of treatment of women with PCOS. COC and AA are more effective than metformin for hyperandrogenic symptoms and endometrial protection. Their combination with metformin adds a positive effect on BMI and glucose tolerance. PROSPERO CRD REGISTRATION NUMBER: CRD42016053457.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Luque-Ramírez M, Nattero-Chávez L, Ortiz Flores AE, et al. Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2018. PMID: 29293982. doi:10.1093/humupd/dmx039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。